Dr. Wally R. Smith, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 23
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
VA license 0101047072
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 23
- Services billed
- 56
- Patients’ average age
- 44
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 63 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Richmond, VA | 211 |
| Hydroxyurea Other prescribers in Richmond, VA | 58 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Richmond, VA | 54 |
| Methadone Hcl Other prescribers in Richmond, VA | 52 |
| Hydromorphone Hcl Other prescribers in Richmond, VA | 49 |
| Oxycontin (oxycodone hcl) Other prescribers in Richmond, VA | 42 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Richmond, VA | 38 |
| Ondansetron Odt (ondansetron) Other prescribers in Richmond, VA | 17 |
| Eliquis (apixaban) Other prescribers in Richmond, VA | 15 |
| Omeprazole Other prescribers in Richmond, VA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 35 payments worth $31,672 in total to this clinician.
| Octapharma USA, Inc. | $13,180 |
|---|---|
| Agios Pharmaceuticals, Inc. | $9,435 |
| Pfizer Inc. | $8,515 |
| Vertex Pharmaceuticals Incorporated | $500 |
| Genetix Biotherapeutics Inc | $41.64 |
| Consulting Fee | $17,078 |
|---|---|
| Travel and Lodging | $10,220 |
| Honoraria | $3,000 |
| Food and Beverage | $1,374 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Octapharma USA, Inc. Aug 21, 2025 | Travel and Lodging travel to ZURICH, Switzerland | $8,231 |
| Octapharma USA, Inc. Aug 21, 2025 | Honoraria | $3,000 |
| Agios Pharmaceuticals, Inc. Jul 30, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,775 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee | $2,450 |
| Pfizer Inc. Dec 15, 2025 | Consulting Fee | $2,450 |
| Agios Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,220 |
| Agios Pharmaceuticals, Inc. Apr 7, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,220 |
| Agios Pharmaceuticals, Inc. Oct 8, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,943 |
| Pfizer Inc. Aug 12, 2025 | Consulting Fee | $1,085 |
| Pfizer Inc. Mar 5, 2025 | Consulting Fee | $1,085 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 15, 2025 | Consulting Fee | $2,450 |
| Agios Pharmaceuticals, Inc. Oct 8, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $1,943 |
| Vertex Pharmaceuticals Incorporated Sep 24, 2025 | Consulting Fee CASGEVY · SICKLE CELL DISEASE/BETA THALESSEMIA | $500 |
| Octapharma USA, Inc. Aug 21, 2025 | Travel and Lodging travel to ZURICH, Switzerland | $8,231 |
| Octapharma USA, Inc. Aug 21, 2025 | Honoraria | $3,000 |
| Octapharma USA, Inc. Aug 21, 2025 | Travel and Lodging travel to ZURICH, Switzerland | $843 |
| Octapharma USA, Inc. Aug 21, 2025 | Travel and Lodging travel to ZURICH, Switzerland | $843 |
| Pfizer Inc. Aug 12, 2025 | Consulting Fee | $1,085 |
| Agios Pharmaceuticals, Inc. Jul 30, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,775 |
| Pfizer Inc. Jul 11, 2025 | Travel and Lodging travel to Alexandria, VA · in-kind | $209 |
| Pfizer Inc. Jul 11, 2025 | Travel and Lodging travel to Alexandria, VA · in-kind | $93.60 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee | $2,450 |
| Pfizer Inc. Jul 8, 2025 | Consulting Fee | $350 |
| Agios Pharmaceuticals, Inc. Apr 7, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,220 |
| Pfizer Inc. Mar 5, 2025 | Consulting Fee | $1,085 |
| Agios Pharmaceuticals, Inc. Feb 7, 2025 | Consulting Fee PYRUKYND · Genetically Defined Disease | $2,220 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $26,386 in research payments for these studies, mostly to the institutions running them.
- A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease
Agios Pharmaceuticals, Inc. - A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06481306
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.